The purpose of this 10-week, double-blind, placebo-controlled study is to determine whether
inflammation impacts reward and motor neural circuitry to contribute to depressive symptoms
like anhedonia and psychomotor slowing in people with Human Immunodeficiency Virus (HIV) and
depression. Sixty male and female patients with HIV who have depression, anhedonia and high
inflammation and are stable on effective treatment for their HIV will be randomized to
receive either the anti-inflammatory drug baricitinib or a placebo for 10 weeks. Participants
will complete lab tests, medical and psychiatric assessments, neurocognitive testing,
functional MRI (fMRI) scans, and optional spinal taps as part of the study. The total length
of participation is about 5 months.